DiaMedica Therapeutics (DMAC) Expected to Announce Quarterly Earnings on Wednesday

DiaMedica Therapeutics (NASDAQ:DMAC) is anticipated to issue its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $13.50 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.17) earnings per share for the quarter, hitting the consensus estimate of ($0.17). The company had revenue of ($0.03) million for the quarter, compared to analyst estimates of $13.50 million. On average, analysts expect DiaMedica Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DiaMedica Therapeutics Stock Up 3.6%

Shares of NASDAQ DMAC traded up $0.22 during mid-day trading on Tuesday, hitting $6.27. 30,850 shares of the company were exchanged, compared to its average volume of 205,416. The stock has a 50 day simple moving average of $7.00 and a 200-day simple moving average of $7.57. DiaMedica Therapeutics has a 1-year low of $3.47 and a 1-year high of $10.42. The firm has a market cap of $337.74 million, a price-to-earnings ratio of -8.91 and a beta of 0.99.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers lifted its holdings in DiaMedica Therapeutics by 14.5% in the third quarter. Rhumbline Advisers now owns 27,357 shares of the company’s stock valued at $188,000 after acquiring an additional 3,463 shares during the period. BNP Paribas Financial Markets lifted its holdings in DiaMedica Therapeutics by 24.4% in the second quarter. BNP Paribas Financial Markets now owns 18,882 shares of the company’s stock valued at $74,000 after acquiring an additional 3,709 shares during the period. Bank of America Corp DE lifted its holdings in DiaMedica Therapeutics by 44.2% in the third quarter. Bank of America Corp DE now owns 12,249 shares of the company’s stock valued at $84,000 after acquiring an additional 3,752 shares during the period. Russell Investments Group Ltd. acquired a new stake in DiaMedica Therapeutics in the third quarter valued at $27,000. Finally, Invesco Ltd. lifted its holdings in DiaMedica Therapeutics by 29.9% in the fourth quarter. Invesco Ltd. now owns 18,628 shares of the company’s stock valued at $148,000 after acquiring an additional 4,293 shares during the period. Institutional investors and hedge funds own 10.12% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on DMAC shares. Lake Street Capital reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Monday, April 20th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.